Callen DF - Search Results

1

Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome.

Callen DF, Ricciardelli C, Butler M, Stapleton A, Stahl J, Kench JG, Horsfall DJ, Tilley WD, Schulz R, Nesland JM, Neilsen PM, Kumar R, Holm R. Callen DF, et al. Oncol Rep. 2010 Apr;23(4):1045-52. doi: 10.3892/or_00000731. Oncol Rep. 2010. PMID: 20204290

2

CBFA2T3-ZNF651, like CBFA2T3-ZNF652, functions as a transcriptional corepressor complex.

Kumar R, Cheney KM, Neilsen PM, Schulz RB, Callen DF. Kumar R, et al. Among authors: callen df. FEBS Lett. 2010 Mar 5;584(5):859-64. doi: 10.1016/j.febslet.2010.01.047. Epub 2010 Jan 30. FEBS Lett. 2010. PMID: 20116376 Free article.

3

Genome-wide mapping of ZNF652 promoter binding sites in breast cancer cells.

Kumar R, Selth LA, Schulz RB, Tay BS, Neilsen PM, Callen DF. Kumar R, et al. Among authors: callen df. J Cell Biochem. 2011 Oct;112(10):2742-7. doi: 10.1002/jcb.23214. J Cell Biochem. 2011. PMID: 21678463

4

Expression of ZNF652, a novel zinc finger protein, in vulvar carcinomas and its relation to prognosis.

Holm R, Knopp S, Kumar R, Lee J, Nesland JM, Tropè C, Callen DF. Holm R, et al. Among authors: callen df. J Clin Pathol. 2008 Jan;61(1):59-63. doi: 10.1136/jcp.2006.045864. Epub 2007 Apr 27. J Clin Pathol. 2008. PMID: 17468294

5

CBFA2T3-ZNF652 corepressor complex regulates transcription of the E-box gene HEB.

Kumar R, Cheney KM, McKirdy R, Neilsen PM, Schulz RB, Lee J, Cohen J, Booker GW, Callen DF. Kumar R, et al. Among authors: callen df. J Biol Chem. 2008 Jul 4;283(27):19026-38. doi: 10.1074/jbc.M709136200. Epub 2008 May 2. J Biol Chem. 2008. PMID: 18456661 Free article.

6

Identification of ANKRD11 as a p53 coactivator.

Neilsen PM, Cheney KM, Li CW, Chen JD, Cawrse JE, Schulz RB, Powell JA, Kumar R, Callen DF. Neilsen PM, et al. Among authors: callen df. J Cell Sci. 2008 Nov 1;121(Pt 21):3541-52. doi: 10.1242/jcs.026351. Epub 2008 Oct 7. J Cell Sci. 2008. PMID: 18840648

7

The oncogenic role of miR-155 in breast cancer.

Mattiske S, Suetani RJ, Neilsen PM, Callen DF. Mattiske S, et al. Among authors: callen df. Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1236-43. doi: 10.1158/1055-9965.EPI-12-0173. Epub 2012 Jun 26. Cancer Epidemiol Biomarkers Prev. 2012. PMID: 22736789 Review.

8

Pre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to drozitumab therapy.

Pishas KI, Neuhaus SJ, Clayer MT, Adwal A, Brown MP, Evdokiou A, Callen DF, Neilsen PM. Pishas KI, et al. Among authors: callen df. Oncol Rep. 2013 Jul;30(1):471-7. doi: 10.3892/or.2013.2454. Epub 2013 May 13. Oncol Rep. 2013. PMID: 23670273

9

Mutant p53 drives invasion in breast tumors through up-regulation of miR-155.

Neilsen PM, Noll JE, Mattiske S, Bracken CP, Gregory PA, Schulz RB, Lim SP, Kumar R, Suetani RJ, Goodall GJ, Callen DF. Neilsen PM, et al. Among authors: callen df. Oncogene. 2013 Jun 13;32(24):2992-3000. doi: 10.1038/onc.2012.305. Epub 2012 Jul 16. Oncogene. 2013. PMID: 22797073

10

Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome.

Neilsen PM, Noll JE, Suetani RJ, Schulz RB, Al-Ejeh F, Evdokiou A, Lane DP, Callen DF. Neilsen PM, et al. Among authors: callen df. Oncotarget. 2011 Dec;2(12):1203-17. doi: 10.18632/oncotarget.382. Oncotarget. 2011. PMID: 22203497 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

261 results

Search Page